Japan PPI inflation slips to 11-mth low in July
Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc. (NASDAQ:RVMD), recently sold a significant portion of the company’s stock. According to a filing with the Securities and Exchange Commission, Goldsmith sold 11,738 shares of common stock on March 17, 2025, at an average price of $39.0403 per share. This transaction amounted to a total value of approximately $458,255. The sale price aligns closely with the current market price of $38.75 and InvestingPro’s Fair Value assessment, suggesting the stock is fairly valued. With a market capitalization of $7.09 billion, Revolution Medicines maintains strong liquidity, as indicated by its current ratio of 14.2.
Following this sale, Goldsmith retains ownership of 441,564 shares directly. Additionally, he holds shares indirectly through various trusts, including the Jonathan Goldsmith Revocable Trust, the Rebecca Eve Goldsmith Trust under the Goldsmith Children’s 2011 Irrevocable Education Trust, and the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
The sale was conducted under a Rule 10b5-1 instruction letter, which was adopted on May 31, 2023, to meet tax obligations related to the vesting of restricted stock units.
In other recent news, Revolution Medicines reported a net loss of $194.6 million for Q4 2024, an increase from the $161.5 million loss in Q4 2023. Despite the higher loss, the company maintains a strong cash position with $2.3 billion, bolstered by $823 million from an equity offering. Needham analysts adjusted their price target for Revolution to $59 from $60, maintaining a Buy rating, following the company’s announcement of two additional registrational trials for its drug daraxonrasib. These trials are aimed at treating pancreatic ductal adenocarcinoma (PDAC) and are expected to begin in the second half of 2025. H.C. Wainwright also updated its outlook, raising the price target to $73 while keeping a Buy rating, citing Revolution’s strong financial standing and potential for significant data catalysts. The company projects a GAAP net loss between $840 million and $900 million for 2025, with increased expenses due to the expansion of clinical development programs. Revolution Medicines is advancing its pipeline of RAS inhibitors, focusing on pivotal trials and potential regulatory approvals. Investors are advised to watch for forthcoming clinical data on zoldonrasib (RMC-9805) in 2025, as per Needham analysts’ notes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.